Nancy Lam, APRN
Family · Dallas, TXNPI 1376136614
Payments from drug & device makers
Across 122 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$432
- Amarin Pharma, Inc.$167
- Pfizer$155
- AstraZeneca$154
- Boehringer Ingelheim$144
- AbbVie$106
- plus $863 from 20 others
What the payments were for
- Food & beverage$2,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $432 |
| Amarin Pharma, Inc. | 9 | $167 |
| Pfizer | 8 | $155 |
| AstraZeneca | 10 | $154 |
| Boehringer Ingelheim | 8 | $144 |
| AbbVie | 6 | $106 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Dexcom, Inc. | 5 | $90 |
| Astellas Pharma US Inc | 5 | $84 |
| Xeris Pharmaceuticals, Inc. | 5 | $81 |
| Amgen | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| GSK | 2 | $49 |
| Bayer | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $35 |
| Exact Sciences | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Shield Therapeutics Inc | 1 | $24 |
| Abbott | 1 | $23 |
| Phadia US Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Lifescan, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Athena Bioscience, LLC | 1 | $10 |
How this compares
$2,020 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $63,019 |
| EliquisApixaban | 33 | $42,425 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $30,239 |
| FarxigaDapagliflozin Propanediol | 13 | $21,102 |
| RybelsusSemaglutide | 15 | $19,215 |
| LinzessLinaclotide | 14 | $10,618 |
| MyrbetriqMirabegron | 20 | $9,274 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,825 |
| Repatha SureclickEvolocumab | 13 | $6,810 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $3,133 |
| Atorvastatin Calcium | 302 | $2,363 |
| Gabapentin | 113 | $2,026 |
| Omeprazole | 91 | $1,924 |
| SynthroidLevothyroxine Sodium | 23 | $1,894 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $1,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $432 | $82,23473 claims |
| PfizerEliquis | $155 | $42,42533 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $154 | $28,92726 claims |
| AbbVieLinzess, Synthroid | $106 | $12,51237 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $9,27420 claims |
| Lilly USA, LLCHumulin 70-30 | $16 | $1,82712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.